Popular diabetes medication recalled by two more pharmaceutical companies - PennLive

Two more pharmaceutical companies have issued a recall for a medication used to control high blood sugar in people with Type 2 diabetes because it may contain a carcinogen.

Lupin Pharmaceuticals Inc. issued the recall for all batches of Metformin Hydrochloride Extended-Release Tablets USP, 500 mg and 1000 mg because “additional analysis revealed that certain tested batches were above the Acceptable Daily Intake Limit for the impurity N-Nitrosodimethylamine (NDMA),” according to a statement posted by the U.S. Food and Drug Administration.

Granules Pharmaceuticals, Inc., recalled 12 lots of its Metformin Hydrochloride Extended-Release Tablets USP, 750 mg, 100 and 500 count.

NDMA is a probable human carcinogen, meaning it could cause cancer.

The U.S. FDA in May had asked pharmaceutical companies to voluntarily recall metformin. At that time, the FDA had recalls from Teva Pharmaceuticals, Marksans Pharma Limited, Apotox Corp. and Amneal Pharmaceuticals.

The details are:

Lupin Metformin Hydrochloride Extended-Release Tablets USP

• 500 mg, NDC No. 68180-338-01, distributed between Nov. 21, 2018, and May 27, 2020.
• 1000 mg, NDC No. 68180-339-09, distributed between Nov. 21, 2018, and May 27, 2020.
• 500 mg, NDC No. 68180-336-07, distributed between Nov. 5, 2018, and May 22, 2020.
• 1000 mg, NDC No. 68180-337-07, distributed between Nov. 5, 2018, and May 22, 2020.
• The medication was distributed in bottles of 60, 90 and 100 tablets and was distributed nationwide in the United States to wholesalers, distributors, drug chain, mail order pharmacies and supermarkets.

For more information, call Inmar Rx Solutions, Inc. at 855-532-1856, between 9 a.m. and 5 p.m. EST, weekdays.

The Granules details are:

Metformin Hydrochloride Extended-Release Tablets USP, 750 mg

• 100 count bottles, NDC No. 70010-492-01, Lot numbers and expiration dates - 4920003A/May 2021, 4920004A/June 2021, 4920005A/June 2021, 4920009A/November 2021, 4920010A/May 2022, 4920011A/June 2022, 4920012A/June 2022, 4920013A/July 2022, 4920014A/July 2022, 4920015A/August 2022 and 4920016A/January 2023.
• 500 count bottles, NDC No. 70010-492-05, lot No. 4920005B, expires June 2021.

The FDA advises consumers to continue taking the medication until they can talk to a doctor.

READ MORE RECALL NEWS

Thanks for visiting PennLive. Quality local journalism has never been more important. We need your support. Not a subscriber yet? Please consider supporting our work.

Let's block ads! (Why?)

"popular" - Google News
July 10, 2020 at 02:34AM
https://ift.tt/2Oe7I9c

Popular diabetes medication recalled by two more pharmaceutical companies - PennLive
"popular" - Google News
https://ift.tt/33ETcgo
Shoes Man Tutorial
Pos News Update
Meme Update
Korean Entertainment News
Japan News Update

Bagikan Berita Ini